Hazard ratio for OS | Univariate | Hazard ratio for PFS | Univariate | Hazard ratio for DMFS | Univariate | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
95.0% CI | p-value | 95.0% CI | p-value | 95.0% CI | p-value | ||||||||
Lower | Upper | Lower | Upper | Lower | Upper | ||||||||
Age <45 vs. ≥45 | 0.497 | 0.185 | 1.331 | 0.164 | 0.655 | 0.319 | 1.346 | 0.250 | 0.807 | 0.353 | 1.845 | 0.611 | |
Sex Male vs. Female | 1.442 | 0.493 | 4.222 | 0.504 | 1.623 | 0.679 | 3.879 | 0.276 | 1.078 | 0.434 | 2.677 | 0.872 | |
WHO type IIA vs. IIB | 1.344 | 0.399 | 4.532 | 0.633 | 1.795 | 0.748 | 4.31 | 0.190 | 2.101 | 0.719 | 6.141 | 0.175 | |
T Stage | 0.152 | 0.026 | 0.119 | ||||||||||
T1 vs. T4 | 0.155 | 0.031 | 0.773 | 0.023 | 0.176 | 0.055 | 0.564 | 0.003 | 0.212 | 0.05 | 0.89 | 0.034 | |
T2 vs. T4 | 0.73 | 0.257 | 2.073 | 0.555 | 0.523 | 0.224 | 1.222 | 0.134 | 0.617 | 0.204 | 1.862 | 0.391 | |
T3 vs. T4 | 0.667 | 0.223 | 1.991 | 0.468 | 0.73 | 0.319 | 1.671 | 0.457 | 0.93 | 0.316 | 2.743 | 0.896 | |
N Stage | 0.740 | 0.501 | 0.188 | ||||||||||
N1 vs. N3 | 1.222 | 0.386 | 3.865 | 0.733 | 0.887 | 0.368 | 2.138 | 0.789 | 0.587 | 0.208 | 1.657 | 0.314 | |
N2 vs. N3 | 0.844 | 0.297 | 2.4 | 0.750 | 0.651 | 0.302 | 1.406 | 0.275 | 0.445 | 0.187 | 1.063 | 0.068 | |
Stage | 0.253 | 0.070 | 0.102 | ||||||||||
Stage II vs. IVa-b | 0.888 | 0.281 | 2.8 | 0.839 | 0.491 | 0.166 | 1.449 | 0.198 | 0.326 | 0.073 | 1.451 | 0.141 | |
Stage III vs. IVa-b | 0.484 | 0.2 | 1.17 | 0.107 | 0.472 | 0.242 | 0.92 | 0.028 | 0.47 | 0.214 | 1.034 | 0.061 | |
Tech SIB vs. SEQ | 1.619 | 0.707 | 3.71 | 0.255 | 1.309 | 0.693 | 2.472 | 0.407 | 1.461 | 0.674 | 3.167 | 0.336 | |
Concurrent chemotherapy 0-5 vs. 6-7 cycles | 1.172 | 0.525 | 2.616 | 0.699 | 0.795 | 0.418 | 1.514 | 0.486 | 0.632 | 0.287 | 1.393 | 0.255 | |
Adjuvant chemotherapy 0-2 vs. 3 cycles | 1.089 | 0.432 | 2.748 | 0.856 | 1.101 | 0.536 | 2.263 | 0.793 | 0.937 | 0.377 | 2.327 | 0.888 | |
Pre-EBV ≥ 2010 vs. < 2010 | 1.760 | 0.524 | 5.915 | 0.360 | 2.309 | 0.819 | 6.512 | 0.114 | 1.595 | 0.550 | 4.625 | 0.390 | |
Mid-EBV detectable vs undetectable | 2.600 | 1.031 | 6.556 | 0.043 | 2.746 | 1.337 | 5.640 | 0.006 | 2.041 | 0.772 | 5.397 | 0.15 | |
Post-EBV detectable vs. undetectale | 5.923 | 1.989 | 17.638 | 0.001 | 5.961 | 2.457 | 14.465 | <0.001 | 29.758 | 8.155 | 108.593 | <0.001 |
3-year OS(95%CI) | p-value | 3-year PFS(95%CI) | p-value | 3-year DMFS(95%CI) | p-value | 3-year LPFS(95%CI) | p-value | 3-year RPFS(95%CI) | p-value | |
---|---|---|---|---|---|---|---|---|---|---|
Pre-EBV < 2010 | 88.4 (73.1–103.7) | 0.360 | 82.9 (65.3–100.5) | 0.114 | 82.9 (62.3–100.5) | 0.386 | 100 | 0.328 | 100 | 0.475 |
Pre-EBV ≥ 2010 | 82.1 (73.9–30.3) | 76.2 (67.0–85.4) | 85.2 (77.0–93.4) | 94.4 (89.1–99.6) | 96.6 (91.9–101.3) | |||||
Undetectable mid-EBV | 86.0 (78.5–93.4) | 0.040 | 81.5 (73.3–89.7) | 0.006 | 86.1 (78.5–93.7) | 0.15 | 97.5 (94.0–101.0) | 0.01 | 98.6 (95.9–101.3) | 0.113 |
Detectable mid-EBV | 66.7 (42.8–90.6) | 52.5 (26.8–78.2) | 76.6 (52.9–100.3) | 79.5 (53.8–105.2) | 87.5 (64.6–110.4) | |||||
Undetectable post-EBV | 86.1 (79.0–93.2) | < 0.001 | 79.9 (71.9–87.9) | < 0.001 | 88.2 (81.3–95.1) | < 0.001 | 97.6 (94.3–100.9) | < 0.001 | 97.2 (93.5–100.9) | 0.841 |
Detectable post-EBV | 42.9 (6.3–79.6) | 42.9 (6.3–79.6) | 22.9 (15.7–61.5) | 33.3 (20.0–86.6) | 100 |
N = 105 | |
---|---|
Age < 45 | 34 (32.4%) |
Age ≥ 45 | 71 (67.6%) |
Sex | |
Male | 82 (78.1%) |
Female | 23 (21.9%) |
T-stage | |
1 | 30 (28.6%) |
2 | 28 (26.7%) |
3 | 29 (27.6%) |
4 | 18 (17.1%) |
N-stage | |
0 | 1 (1.0%) |
1 | 26 (24.8%) |
2 | 57 (54.3%) |
3 | 21 (20.0%) |
Stage grouping (AJCC 2010) | |
II | 14 (13.3%) |
III | 54 (51.4%) |
IVa-b | 37 (35.2%) |
WHO subtypes | |
2A | 11 (10.5%) |
2B | 94 (89.5%) |
Mid-EBV | |
undetectable | 90 (85.7%) |
detectable | 15 (14.3%) |
Post-EBV | |
undetectable | 98 (93.3%) |
detectable | 7 (6.7%) |
Hazard ratio for OS | 95.0% CI for OS | P-value | ||
---|---|---|---|---|
Lower | Upper | |||
Age < 45 vs. ≥ 45 | 0.409 | 0.140 | 1.190 | 0.101 |
T | 0.305 | |||
T1 vs. T4 | 0.286 | 0.052 | 1.570 | 0.150 |
T2 vs. T4 | 1.214 | 0.361 | 4.078 | 0.754 |
T3 vs. T4 | 1.177 | 0.341 | 4.069 | 0.796 |
Mid-EBV undetectable vs detectable | 1.620 | 0.617 | 4.251 | 0.327 |
Post-EBV undetectable vs. detectable | 6.881 | 1.699 | 27.867 | 0.007 |
Age <45 vs. ≥ 45 | 0.422 | 0.180 | 0.988 | 0.047 |
WHO type IIA vs. IIB | 1.354 | 0.441 | 4.159 | 0.597 |
T Stage | 0.101 | |||
T1 vs. T4 | 0.497 | 0.104 | 2.375 | 0.381 |
T2 vs. T4 | 1.660 | 0.450 | 6.125 | 0.446 |
T3 vs. T4 | 2.099 | 0.646 | 6.825 | 0.218 |
Stage | 0.099 | |||
Stage II vs. IVa-b | 1.016 | 0.256 | 4.035 | 0.982 |
Stage III vs. IVa-b | 0.416 | 0.170 | 1.021 | 0.055 |
EBV < 2010 vs. ≥ 2010 | 0.370 | 0.113 | 1.211 | 0.100 |
Mid-EBV undetectable vs. detectable | 1.427 | 0.630 | 3.234 | 0.394 |
Post-EBV undetectable vs. detectable | 5.117 | 1.562 | 16.768 | 0.007 |
WHO type IIA vs. IIB | 1.653 | 0.470 | 5.810 | 0.433 |
T Stage | 0.113 | |||
T1 vs. T4 | 0.945 | 0.068 | 13.158 | 0.966 |
T2 vs. T4 | 5.632 | 0.388 | 81.647 | 0.205 |
T3 vs. T4 | 4.628 | 0.384 | 55.737 | 0.228 |
N Stage | 0.410 | |||
N1 vs. N3 | 4.484 | 0.305 | 65.955 | 0.274 |
N2 vs. N3 | 2.018 | 0.151 | 26.935 | 0.595 |
Stage | 0.340 | |||
Stage II vs. IVa-b | 0.090 | 0.003 | 2.435 | 0.153 |
Stage III vs. IVa-b | 0.150 | 0.009 | 2.474 | 0.185 |
Mid-EBV undetectable vs detectable | 1.583 | 0.517 | 4.843 | 0.421 |
Post-EBV undetectable vs. detectable | 129.071 | 19.031 | 875.364 | 0.000 |